Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,229 recruiting studies in this area right now.
By phase
- Not applicable3,142
- Phase 21,065
- Phase 1822
- Phase 1/Phase 2446
- Phase 3423
- Phase 4237
- Phase 2/Phase 394
Top conditions
- Multiple Sclerosis341
- Multiple Myeloma332
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis142
- Type 1 Diabetes133
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia123
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)65
- Leukemia64
- Acute Myeloid Leukemia62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals63
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California492
- Maryland196
- Alabama176
- Florida143
- Arizona141
- New York123
- Massachusetts119
- Texas117
- Illinois82
- Colorado77
Recruiting studies6,229 total
- NCT04262492Recruiting
Registry of adults with APS on blood thinners
This study keeps an international registry of people with antiphospholipid syndrome (APS) who are taking direct oral blood thinners. It may help doctors better understand how APS patients do over time and improve future care, even if you’re not asked to change treatment.
NancyAges Any age - NCT04263935Recruiting
Lymphoma gene changes and what they mean for outcomes
This study looks at lymphoma’s DNA “driver gene” changes and how they relate to symptoms, lab findings, and prognosis (how the disease is expected to do over time). It may help doctors better predict outcomes for people with lymphoma based on their tumor biology.
Zhengzhou, HenanAges Any age - NCT04268199RecruitingPhase 2
At-home chemotherapy teaching for people with myeloma
This study tests whether people with symptomatic myeloma can safely learn to give themselves chemotherapy at home. It aims to make treatment easier while tracking safety and whether treatment is done correctly.
Calgary, AlbertaAges 18 years+ - NCT04271644RecruitingPhase 1/Phase 2
CAR-T treatment targeting BCMA for hard-to-treat myeloma
This Phase 1/2 study tests a BCMA-targeting CAR-T cell therapy for people with relapsed or refractory multiple myeloma or related plasma cell diseases. It may help by using your own immune cells, engineered to recognize a specific target on cancer cells.
Kunming, YunnanAges 18–75 - NCT04280510Recruiting
Study of immune-related gut illnesses in adults
This study looks at adults with immune-related stomach and intestine problems to better understand what may cause them. If you qualify, you can share information and consent to help researchers learn how these conditions work.
CréteilAges 18 years+ - NCT04290000Recruiting
Share samples after CAR-T treatment at Montpellier hospital
This study collects and stores biological samples from people who have been treated with CAR-T cells at the University Hospital of Montpellier. Your samples can help researchers learn more about treatment effects and safety.
MontpellierAges 18 years+ - NCT04292067Recruiting
Study gut bacteria in people with arthritis
This study compares the gut microbiome (the bacteria in your intestines) in adults with spondyloarthritis or rheumatoid arthritis versus healthy adults. It aims to better describe differences that may help explain these diseases.
Boulogne-BillancourtAges 18 years+ - NCT04300101Recruiting
Study of a blood- and tissue-based index in large B-cell lymphoma
This study looks at a “Mixed Molecular Clinical Index” (MMCI), which combines test results from lymphoma tissue and clinical information. It aims to help better understand how diffuse large B-cell lymphoma behaves and how patients may respond to standard first-line treatment.
Meldola, FCAges 18 years+ - NCT04300998Recruiting
CAR-T therapy study for older adults
This study looks at how well CAR-T cell therapy works and how safely it can be given to older adults. It is for people whose cancer or related blood condition has come back or did not respond, and who are receiving a standard (commercial) CAR-T product.
New York, New YorkAges 60 years+ - NCT04303117RecruitingPhase 1/Phase 2
Test drug PDS01ADC alone and with immunotherapy for Kaposi sarcoma
This Phase 1/2 study tests PDS01ADC, a targeted cancer drug, for advanced Kaposi sarcoma (KS). It also studies how well the drug works when added to the immunotherapy M7824, especially if KS has not responded to prior treatments.
Bethesda, MarylandAges 18–99 - NCT04304820RecruitingPhase 2
Testing early oral cyclosporine and eltrombopag for severe anemia
This Phase 2 study tests whether starting two oral medicines early—cyclosporine and eltrombopag—can improve severe aplastic anemia in people who have not had prior treatment for it. It may help your blood counts recover without needing stronger or earlier treatments.
Bethesda, MarylandAges 3–99 - NCT04307667Recruiting
Study brain immune activity in people with mild asthma
This trial studies how immune cells in the brain (called microglia) may be activated in asthma. You may be able to help researchers test whether a specific “immune pathway” differs in certain asthma patients using brain scans and breathing/allergy testing.
Madison, WisconsinAges 18–75 - NCT04308564Recruiting
Study of lab and clinic data in antiphospholipid patients
This study looks at lab results and clinic information in people who have antiphospholipid antibodies. The goal is to better understand these antibody-positive conditions and what happens over time, which may help improve care.
LilleAges 18 years+ - NCT04320680Recruiting
Study visits for adults with lupus in Brest, France
This study focuses on people aged 18 and older with lupus who attend a multi-team clinic visit in Brest, France. It mainly looks at whether you can participate in the multidisciplinary consultation and its related study procedures.
BrestAges 18–80 - NCT04314219RecruitingPhase 3
Preventing GVHD after leukemia stem cell transplant
This Phase 3 study tests whether giving post-transplant cyclophosphamide can better prevent a dangerous immune complication called GVHD compared with the usual standard medicines. You may be eligible if you are in remission from acute leukemia and planning a fully matched related-donor stem cell transplant.
RiyadhAges 14–65 - NCT04314752Recruiting
Study on multiple myeloma disparities in California patients
This study builds research tools to better understand and address differences in multiple myeloma outcomes for different groups. You may be able to help if you were diagnosed recently and live in California.
Sacramento, CaliforniaAges 21 years+ - NCT04319367RecruitingPhase 2
Antibody treatment added to HIV meds for early HIV
This Phase 2 trial tests whether adding long-acting HIV antibodies to standard HIV treatment (ART) can help control HIV in people who started ART soon after getting infected. It also checks how safe the antibody treatment is and how well it works over time.
AarhusAges 18–60 - NCT04318678RecruitingPhase 1
CD123 CAR T-cell therapy for relapsed leukemia and related cancers
This early-phase study tests a lab-made immune therapy (CD123 CAR T cells) for children and young adults up to age 21 whose cancer has come back or didn’t respond to treatment. The goal is to see if these CAR T cells can find and attack cancer cells that carry a marker called CD123.
Memphis, TennesseeAges Up to 21 years - NCT04323748RecruitingPhase 1
Testing a stronger rituximab dose schedule for new ITP
This trial studies whether a “dose-dense” rituximab schedule can help children and teens with newly diagnosed, high-risk immune thrombocytopenia (ITP). It aims to raise/maintain platelet counts and control bleeding, while carefully checking safety.
Vahalla, New YorkAges 1–21 - NCT04326218Recruiting
Understanding Immune Causes of Kidney Membrane Disease
This study examines blood and kidney tissue samples from people with membranous nephropathy—a condition where the kidney's filtering membrane is damaged by the immune system. Researchers are trying to understand which immune markers predict how the disease will progress and respond to treatment.
Nice, Alpes MaritimeAges 18 years+ - NCT04329728RecruitingPhase 1/Phase 2
Study drug for relapsed or refractory lymphoid cancers
This Phase 1/2 study tests AVM0703 in people ages 12+ with certain lymphoid cancers that have returned or not responded to treatment. It may help shrink the cancer or control it when other treatments have failed or are not possible.
Duarte, CaliforniaAges 12–95 - NCT04330118Recruiting
Study immune cells in DRESS and drug rash reactions
This trial studies how certain immune cells (eosinophils) behave during severe drug reactions like DRESS and during milder drug rashes. It may help doctors understand what drives organ damage and improve how these reactions are managed.
ArrasAges 18 years+ - NCT04330287Recruiting
Study of heart health in adults aging with HIV
This study looks at how aging affects heart health in people who have HIV. It may help researchers find better ways to prevent or monitor heart problems over time.
Essen, NordrheinwestfalenAges 18 years+ - NCT04331353Recruiting
Asthma trial to reduce cockroach exposure at home
This study looks at whether reducing cockroaches in a child’s home can improve asthma control and reduce asthma flare-ups. It enrolls children who have ongoing (uncontrolled) asthma and will spend most nights in the study home.
New Orleans, LouisianaAges 5–17
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,229 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,721 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.